Gilead Sciences Inc - GILD STOCK NEWS

Gilead Sciences (GILD) has announced its executive participation in two upcoming investor conferences in March. The company will present at the TD Cowen Annual Health Care Conference on March 4 at 11:10 AM ET and the Leerink Partners Global Healthcare Conference on March 11 at 10:40 AM ET.

Live webcasts will be available on Gilead's investor page (investors.gilead.com), with replays accessible for at least 30 days post-presentation. Gilead Sciences is a biopharmaceutical company with over three decades of breakthrough medical achievements, focusing on innovative medicines for HIV, viral hepatitis, COVID-19, and cancer treatments. The company maintains operations in more than 35 countries, with its headquarters in Foster City, California.

Gilead Sciences announced that the FDA has accepted its New Drug Application for lenacapavir, a twice-yearly injectable HIV prevention treatment, under priority review with a PDUFA date of June 19, 2025. The application follows Breakthrough Therapy Designation granted in October 2024.

The NDAs are supported by Phase 3 trials PURPOSE 1 and PURPOSE 2. PURPOSE 1 showed 100% risk reduction in cisgender women, with zero infections in the lenacapavir group. PURPOSE 2 demonstrated 99.9% effectiveness with a 96% risk reduction among cisgender men and gender-diverse people, with only two HIV infections reported.

Gilead has also submitted applications to the European Medicines Agency for review under accelerated assessment, including an EU-M4all application to facilitate availability in low and lower-middle-income countries.

Gilead Sciences (GILD) has announced a 2.6% increase in its quarterly cash dividend, which will take effect in the first quarter of 2025. The new dividend will be $0.79 per share of common stock, payable on March 28, 2025, to stockholders of record as of March 14, 2025.

The dividend increase demonstrates the company's commitment to returning value to shareholders, though future dividends will remain subject to Board approval. Gilead Sciences continues its focus on developing innovative medicines for HIV, viral hepatitis, COVID-19, cancer, and inflammation, with operations spanning more than 35 countries worldwide.

Gilead Sciences (GILD) reported strong financial results for Q4 and full year 2024. Total revenue increased 6% to $28.8 billion for the full year, driven by higher sales in HIV, Oncology, and Liver Disease. Product sales excluding Veklury grew 8% to $26.8 billion.

Key highlights include Biktarvy sales increasing 13% to $13.4 billion, HIV product sales rising 8% to $19.6 billion, and Oncology sales growing 12% to $3.3 billion for full year 2024. The company's cash position strengthened to $10.0 billion by year-end.

For 2025 guidance, Gilead expects product sales between $28.2-28.6 billion, with non-Veklury sales of $26.8-27.2 billion. The company projects diluted EPS of $5.95-6.35 and non-GAAP diluted EPS of $7.70-8.10.

Cognizant (NASDAQ: CTSH) has expanded its partnership with Gilead Sciences (NASDAQ: GILD) to enhance value creation through advanced technology applications. The expanded agreement focuses on delivering cost leadership and productivity improvements through AI-driven solutions.

The collaboration will leverage Cognizant's Neuro AI generative AI platform to accelerate value creation, enhance IT and business processes, and improve operational efficiencies across customer service, employee interactions, and business value management. The partnership aims to generate significant cost savings that can be reinvested into Gilead's core life sciences business.

Building on their decade-long relationship supporting Gilead's global IT infrastructure, Cognizant will implement custom-built Gen AI solutions to transform user experience and boost operational efficiency. This expansion enables Gilead to focus on its mission of developing treatments for cancer, HIV, and other diseases while optimizing its technological capabilities.

Gilead Sciences (GILD) has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025, after market close. The company's management will host a webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update, including 2025 guidance.

The live webcast will be accessible through the Investors section of Gilead's website and will remain archived there for one year. The biopharmaceutical company, headquartered in Foster City, California, operates in more than 35 countries and focuses on developing innovative medicines for HIV, viral hepatitis, COVID-19, and cancer.

Gilead Sciences (NASDAQ: GILD) and LEO Pharma announced a strategic partnership focused on developing LEO Pharma's preclinical oral STAT6 programs for inflammatory diseases. The partnership includes small molecule inhibitors and targeted protein degraders targeting STAT6, a transcription factor important for IL-4 and IL-13 cytokine signaling.

Under the agreement, Gilead will acquire global rights to develop and commercialize the oral STAT6 program, while LEO Pharma retains global rights for topical formulations in dermatology. LEO Pharma has the option to co-commercialize oral programs for dermatology outside the U.S.

The deal includes an upfront payment of $250 million to LEO Pharma, with potential total payments reaching $1.7 billion plus tiered royalties ranging from high single-digit to mid-teens on oral STAT6 product sales. The transaction is expected to reduce Gilead's GAAP and non-GAAP 2025 EPS by approximately $0.15-$0.17.

Gilead Sciences (NASDAQ: GILD) has announced its participation in the upcoming J.P. Morgan Healthcare Conference scheduled for January 13, 2025. The presentation will begin at 11:15 a.m. Pacific Time and will be accessible via live webcast on investors.gilead.com, with replay available for at least 30 days.

Gilead Sciences is a biopharmaceutical company with over three decades of breakthrough medical achievements. The company focuses on developing innovative medicines for life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Operating in more than 35 countries worldwide, Gilead is headquartered in Foster City, California.

Gilead Sciences (Nasdaq: GILD) announced that the U.S. FDA has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after platinum-based chemotherapy. This designation is based on positive results from the Phase 2 TROPiCS-03 study, which showed promising antitumor activity and a consistent safety profile. Gilead plans to initiate a Phase 3 clinical trial in this patient population. Lung cancer is the second most diagnosed cancer in the U.S., with SCLC accounting for about 15% of cases. Approximately 70% of SCLC diagnoses are at the extensive stage, where current treatment options are and prognosis is poor. Trodelvy, a Trop-2-directed antibody-drug conjugate, is already approved for certain types of metastatic breast cancer and is being explored for multiple other cancers.